TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 93 filers reported holding TCR2 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $351 | -95.0% | 234 | -93.7% | 0.00% | – |
| Q3 2022 | $7,000 | -84.4% | 3,699 | -61.9% | 0.00% | – |
| Q4 2021 | $45,000 | -90.3% | 9,701 | -82.3% | 0.00% | – |
| Q3 2021 | $466,000 | +85.7% | 54,728 | +258.6% | 0.00% | – |
| Q2 2021 | $251,000 | -79.0% | 15,262 | -71.8% | 0.00% | – |
| Q1 2021 | $1,194,000 | +2495.7% | 54,070 | +3533.7% | 0.00% | – |
| Q4 2020 | $46,000 | +666.7% | 1,488 | +433.3% | 0.00% | – |
| Q3 2020 | $6,000 | -92.4% | 279 | -94.6% | 0.00% | – |
| Q2 2020 | $79,000 | +49.1% | 5,169 | -24.4% | 0.00% | – |
| Q1 2020 | $53,000 | -74.3% | 6,835 | -52.7% | 0.00% | – |
| Q4 2019 | $206,000 | +52.6% | 14,453 | +61.1% | 0.00% | – |
| Q3 2019 | $135,000 | +487.0% | 8,972 | +461.8% | 0.00% | – |
| Q2 2019 | $23,000 | +2200.0% | 1,597 | +4890.6% | 0.00% | – |
| Q1 2019 | $1,000 | – | 32 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |